LCM
SPRY icon

Legato Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Legato Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-109,095
Closed -$1.27M – 873
2025
Q4 		$1.27M Buy
109,095
+69,685
+177% +$678K 0.11% 293
2025
Q3 		$396K Sell
39,410
-64,723
-62% -$929K 0.04% 472
2025
Q2 		$1.82M Buy
104,133
+7,542
+8% +$109K 0.22% 130
2025
Q1 		$1.22M Buy
96,591
+75,130
+350% +$904K 0.16% 199
2024
Q4 		$226K Sell
21,461
-2,891
-12% -$40.5K 0.03% 517
2024
Q3 		$353K Buy
+24,352
New +$290K 0.04% 487

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Legato Capital Management's SPRY Position: Q1 2026 in Review

Legato Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 109,095 shares — an estimated $1.27M sold.

Legato Capital Management first reported a position in SPRY in Q3 2024 and held it in 6 quarters. The position peaked at $1.82M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Legato Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 109,095 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.27M.
  • Legato Capital Management first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Legato Capital Management's ARS Pharmaceuticals position peaked at $1.82M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.